Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1998 Jul;78(1):28–33. doi: 10.1038/bjc.1998.437

Clinical benefit from palliative chemotherapy in non-small-cell lung cancer extends to the elderly and those with poor prognostic factors.

T F Hickish 1, I E Smith 1, M E O'Brien 1, S Ashley 1, G Middleton 1
PMCID: PMC2062937  PMID: 9662246

Abstract

The intention of this study was to identify the pretreatment characteristics predicting for the survival, objective response and symptom relief in patients with non-resectable, non-small-cell lung cancer (NSCLC) managed in the Lung Unit at the Royal Marsden Hospital. This analysis included 290 patients with advanced NSCLC generally treated with a cisplatin-based chemotherapy regimen in one of a series of trials. Thirty-seven pretreatment variables, response and survival data were collected prospectively and analysed using univariate and multivariate methods. By multivariate analysis performance status, disease extent and pattern of metastases along with certain biochemical features were influential independent variables for survival, objective and symptom response. Older age was positively associated with objective response (P = 0.04). When the independent factors for symptom response were used to group patients into prognostic categories, 30-48% of patients with an adverse set of factors had symptom relief. Similarly using the relative risk of death to subgroup the patient population, 54% of patients at high risk of death (greater than 8.0), with a median survival of 2.5 months, had symptom relief. The data are consistent with other studies in identifying the pretreatment factors predicting for survival and objective response. Additionally, older age is positively associated with objective response and the majority of patients with the worst prognosis have symptom relief from treatment with chemotherapy.

Full text

PDF
28

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Albain K. S., Crowley J. J., LeBlanc M., Livingston R. B. Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience. J Clin Oncol. 1991 Sep;9(9):1618–1626. doi: 10.1200/JCO.1991.9.9.1618. [DOI] [PubMed] [Google Scholar]
  2. Breslow N. E., Day N. E. Statistical methods in cancer research. Volume I - The analysis of case-control studies. IARC Sci Publ. 1980;(32):5–338. [PubMed] [Google Scholar]
  3. Ellis P. A., Smith I. E., Hardy J. R., Nicolson M. C., Talbot D. C., Ashley S. E., Priest K. Symptom relief with MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in advanced non-small-cell lung cancer. Br J Cancer. 1995 Feb;71(2):366–370. doi: 10.1038/bjc.1995.74. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Ellis P. A., Talbot D. C., Nicolson M. C., Priest K., Ashley S., Smith I. E. A pilot study of mitomycin, cisplatin and continuous infusion 5-fluorouracil (MCF) in advanced non-small-cell lung cancer. Br J Cancer. 1995 Jun;71(6):1315–1318. doi: 10.1038/bjc.1995.255. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Fukuoka M., Masuda N., Furuse K., Negoro S., Takada M., Matsui K., Takifuji N., Kudoh S., Kawahara M., Ogawara M. A randomized trial in inoperable non-small-cell lung cancer: vindesine and cisplatin versus mitomycin, vindesine, and cisplatin versus etoposide and cisplatin alternating with vindesine and mitomycin. J Clin Oncol. 1991 Apr;9(4):606–613. doi: 10.1200/JCO.1991.9.4.606. [DOI] [PubMed] [Google Scholar]
  6. Jaakkimainen L., Goodwin P. J., Pater J., Warde P., Murray N., Rapp E. Counting the costs of chemotherapy in a National Cancer Institute of Canada randomized trial in nonsmall-cell lung cancer. J Clin Oncol. 1990 Aug;8(8):1301–1309. doi: 10.1200/JCO.1990.8.8.1301. [DOI] [PubMed] [Google Scholar]
  7. Kawahara M., Furuse K., Kodama N., Yamamoto M., Kubota K., Takada M., Negoro S., Kusunoki Y., Matui K., Takifuji N. A randomized study of cisplatin versus cisplatin plus vindesine for non-small cell lung carcinoma. Cancer. 1991 Aug 15;68(4):714–719. doi: 10.1002/1097-0142(19910815)68:4<714::aid-cncr2820680408>3.0.co;2-j. [DOI] [PubMed] [Google Scholar]
  8. Luedke D. W., Einhorn L., Omura G. A., Sarma P. R., Bartolucci A. A., Birch R., Greco F. A. Randomized comparison of two combination regimens versus minimal chemotherapy in nonsmall-cell lung cancer: a Southeastern Cancer Study Group Trial. J Clin Oncol. 1990 May;8(5):886–891. doi: 10.1200/JCO.1990.8.5.886. [DOI] [PubMed] [Google Scholar]
  9. Mainwaring P. N., Nicolson M. C., Hickish T., Penson R., Joel S., Slevin M., Smith I. E. Continuous infusional topotecan in advanced breast and non-small-cell lung cancer: no evidence of increased efficacy. Br J Cancer. 1997;76(12):1636–1639. doi: 10.1038/bjc.1997.609. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Miller A. B., Hoogstraten B., Staquet M., Winkler A. Reporting results of cancer treatment. Cancer. 1981 Jan 1;47(1):207–214. doi: 10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6. [DOI] [PubMed] [Google Scholar]
  11. O'Connell J. P., Kris M. G., Gralla R. J., Groshen S., Trust A., Fiore J. J., Kelsen D. P., Heelan R. T., Golbey R. B. Frequency and prognostic importance of pretreatment clinical characteristics in patients with advanced non-small-cell lung cancer treated with combination chemotherapy. J Clin Oncol. 1986 Nov;4(11):1604–1614. doi: 10.1200/JCO.1986.4.11.1604. [DOI] [PubMed] [Google Scholar]
  12. Paesmans M., Sculier J. P., Libert P., Bureau G., Dabouis G., Thiriaux J., Michel J., Van Cutsem O., Sergysels R., Mommen P. Prognostic factors for survival in advanced non-small-cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1,052 patients. The European Lung Cancer Working Party. J Clin Oncol. 1995 May;13(5):1221–1230. doi: 10.1200/JCO.1995.13.5.1221. [DOI] [PubMed] [Google Scholar]
  13. Shepherd F. A. Future directions in the treatment of non-small cell lung cancer. Semin Oncol. 1994 Jun;21(3 Suppl 4):48–62. [PubMed] [Google Scholar]
  14. Souquet P. J., Chauvin F., Boissel J. P., Cellerino R., Cormier Y., Ganz P. A., Kaasa S., Pater J. L., Quoix E., Rapp E. Polychemotherapy in advanced non small cell lung cancer: a meta-analysis. Lancet. 1993 Jul 3;342(8862):19–21. doi: 10.1016/0140-6736(93)91882-m. [DOI] [PubMed] [Google Scholar]
  15. Veronesi A., Magri M. D., Tirelli U., Carbone A., Mazza F., Franceschi S., Talamini R., Ardizzoni A., Canobbio L., Rosso R. Chemotherapy of advanced non-small-cell lung cancer with cyclophosphamide, adriamycin, methotrexate, and procarbazine versus cisplatin and etoposide. A randomized study. Am J Clin Oncol. 1988 Oct;11(5):566–571. doi: 10.1097/00000421-198810000-00012. [DOI] [PubMed] [Google Scholar]
  16. Weick J. K., Crowley J., Natale R. B., Hom B. L., Rivkin S., Coltman C. A., Jr, Taylor S. A., Livingston R. B. A randomized trial of five cisplatin-containing treatments in patients with metastatic non-small-cell lung cancer: a Southwest Oncology Group study. J Clin Oncol. 1991 Jul;9(7):1157–1162. doi: 10.1200/JCO.1991.9.7.1157. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES